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Abstract 
Background Major developments in the prevention and treatment of human 
immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) 
have taken place in recent years. Changes in the size of the HIV and AIDS epidemic need to 
be monitored to assess these developments and plan future services. 
Aims To describe temporal trends in the incidence of HIV and AIDS in Ireland, describing 
separately the major risk groups, and to explore possible associations between these trends 
with developments in care. 
Methods The annual numbers of HIV and AIDS in Ireland were analysed to determine 
whether there has been a turning point in incidence. 
Results For AIDS, there has been an overall decrease in numbers since 1993, with both 
homosexual and intravenous drug users (IDU) risk groups exhibiting a decrease. For HIV 
antibody positive individuals, overall numbers have remained constant. However, there has 
been an upward trend in the heterosexual risk group and a downward trend in the IDU risk 
group. Thus both AIDS and HIV numbers exhibit turning points. 
Conclusions Declines in HIV and AIDS incidence in the homosexual and IDU risk groups 
are indirectly attributable to health safety and treatment programmes. The increase in HIV 
antibody positive cases among heterosexuals may reflect a relapse in safe sex behaviour. 
Introduction 
The first cases of AIDS in Ireland were reported in 1982.1 Since then, there have been major 
developments in health-care both internationally2,3 and in Ireland.4 The current standard of 
care for the treatment of HIV infection involves initiating highly aggressive antiretroviral 
therapy (HAART) at an early stage of infection. Treatment usually consists of a triple 
combination of dual nucleoside reverse transcriptase inhibitors, with either a protease 
inhibitor or a non-nucleoside reverse transcriptase inhibitor. It is important to ascertain what 
effect these developments have had on the AIDS epidemic and to predict future trends. 
 The impact of prevention measures also needs to be assessed. These include the 
introduction of the safe sex programme by the Department of Health and Children and the 
introduction of needle sharing exchange centres in 1989.5 
 Recent reports from other countries6,7 have described changing patterns in HIV and 
AIDS incidence. Similar studies have not been undertaken in Ireland and therefore an 
overview of available data is presented here. We examined the AIDS and HIV data’ for 
turning points, examining separately die three major risk groups: homosexuals, IDU and 
heterosexuals. An analysis of the total number of HIV antibody tests as reported by the Virus 
Reference Laboratory was also performed. 
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Methods 
Statistical analysis 
The problem of determining whether there has been a change in numbers of HIV antibody 
positive and AIDS cases is formulated as that of locating the maximum (or minimum) of a 
Poisson quadratic regression. The assumption is that die number of HIV antibody positive 
cases in year t has a Poisson distribution with mean µ(t). The mean µ(t) is assumed to be a 
quadratic function of t, i.e. µ(t) = a0 + a1t + a2t2. The ‘goodness of fit’ of the model is 
determined using the likelihood ratio statistic. Standard maximum likelihood estimates â0, â1 
and â2 are found for the parameters a0, a1 and a2 respectively, together with associated 
standard errors. A likelihood ratio test is used to determine if the parameter Oh is non-zero. If 
so, by differentiating the function µ(t), we see the turning point, denoted by to, is then given 
by t0=-0.5a1/a2. It is estimated by ^t0=-0.5 â1/â2. If â2 is not significantly different from zero, 
then the â2 term is omitted from the model. Estimates of â0 and â1 are recomputed. If â1 is 
significantly different from zero, then an increasing or decreasing trend in the mean function 
µ(t) is indicated. 
 This Poisson model is also used in analysing the AIDS data. This method has been used 
previously in a similar study in the US.8 Fieller’s theorem is used to find confidence intervals 
for the location of turning points.9 
 Linear regression was used to determine if the annual number of HIV antibody tests has 
changed significantly over time. 
 Results are reported as estimates of the turning points with associated 95% 
confidence intervals. When no turning point exists, significant increasing or decreasing 
trends are reported. 
Results 
AIDS incidence 
The numbers of AIDS cases in Ireland to December 1999, as reported to the Department of 
Health and Children are given in Table 1. The number of cases of AIDS together with the 
numbers predicted by the Poisson quadratic regression model, by year of diagnosis, is shown 
in Figure 1. A likelihood ratio test determined that a change point occurred in the incidence 
over time (p<0.0001). It was estimated to be July 1993 with 95% confidence interval 
(December 1992 to May 1994). There was an increasing trend before the change point and a 
decrease thereafter. For the homosexuals, the estimate was July 1993 with 95% confidence 
interval (June 1992 to July 1995). For the IDUs it was February 1993 with 95% confidence 
interval (July 1992 to October 1993). The difference in the two groups was not statistically 
significant. The numbers of AIDS cases in the heterosexual risk group were too small for 
analysis (see Table 1). 
HIV incidence 
The numbers of HIV antibody positive cases to September 1999 by annual time period of 
diagnosis by the Virus Reference Laboratory and reported to the Department of Health and 
Children are shown in Table 2. When no category was identified, the risk group was declared 
unspecified. Due to historical reasons, the reports on HIV statistics issued by the Department 
of Health and Children amalgamate the figures in the heterosexual and risk unspecified 
groups. Separate figures are not presently available. 
 
 
 
Table 1: AIDS cases by risk group and year of diagnosis 
Category IV drug 
users 
Homo- 
sexual 
Hetero- 
sexual 
Other Total  
1982 0 2 0 0 2 
1983 0 0 0 1 1 
1984 0 1 0 2 3 
1985 1 1 0 3 5 
1986 1 1 0 4 6 
1987 9 6 1 4 20 
1988 10 21 1 6 38 
1989 21 17 2 11 51 
1990 27 22 8 4 61 
1991 31 23 11 6 71 
1992 27 15 7 1 50 
1993 42 13 11 2 68 
1994 21 27 7 12 67 
1995 23 16 10 6 55 
1996 33 34 11 1 79 
1997 9 12 7 4 32 
1998 11 13 5 12 41 
1999 14 13 9 5 41 
Table 2: HIV antibody positive cases by risk group and year of diagnosis 
Category IV drug 
Users 
Homo- 
sexuals 
Hetero/risk 
Unspecified 
Other Total positive 
Individuals 
Total No. 
of Tests 
1985* 221 39 0 103 363  
1986 112 11 21 25 169 4,743 
1987 72 21 26 26 145 768 
1988 58 17 20 20 115 8177 
1989 57 33 0 26 116 10,085 
1990 50 25 24 12 111 10,405 
1991 34 27 25 6 92 10,143 
1992 82 5 50 11 201 13,005 
1993 52 48 21 16 137 13,253 
1994 20 31 22 12 85 14,126 
1995 19 33 30 9 91 13,558 
1996 20 41 27 18 106 14,452 
1997 21 37 40 21 119 14,742 
1998 26 37 47 26 136 18,303 
To Sept. 
1999 58 23 43 27 151 15,880 
*Cumulative numbers 
  
The data were analysed, again using the Poisson quadratic regression model. The model 
indicated that the number of HIV positive cases has remained roughly constant over time, but 
not in the individual risk groups. There has been a significant upward trend in the 
heterosexual/risk unspecified group (p<0.01) and there has been a significant downward trend 
in the IDU risk group (p<0.002). In the homosexual risk group, there has been a turning point 
(p<0.001) in the number of HIV antibody positive cases. The peak is estimated to have 
occurred in November 1993. The data are illustrated in Figure 2, which shows the number of 
HIV positive individuals in each of the risk groups over time. 
HIV tests 
The total number of HIV tests to September 1999 by annual time period in which the test was 
analysed by the Virus Reference Laboratory and reported to the Department of Health and 
Children is shown in Table 2. Note that a case refers to an individual, while the same 
individual may or may not account for more than one test. 
 The regression model of number of HIV tests over time showed that the number of 
tests has increased over time, as can be seen in Table 2. Data on the annual number of HIV 
antibody tests per risk group were available, only for the years 1995 to (September) 1999. The 
annual number of tests for each of the three risk groups being considered here has increased in 
this time. 
 In these latter years, the heterosexual/risk unspecified group has accounted for 
approximately 74% of tests for the three risk groups (carried out annually), and it has not 
changed in these five years. The cumulative proportion of positive individuals out of total 
tests carried out in this group is also constant, at approximately 66% in each of these five 
years. 
 
 
 
 
Discussion 
We have found in this study that both homosexual and IDU risk groups exhibit a decrease in 
AIDS incidence at approximately the same time – 1993. This is consistent with reports in the 
UK.6 The decrease is perhaps a consequence of the use of HAART. A dramatic reduction in 
AIDS incidence in the US coincided with the introduction of HAART, specifically protease 
inhibitor therapy.10 Palella et al11 showed a dramatic reduction in the incidence of the three 
most common opportunistic infections, Pneumocystis carinii pneumonia (PCP), 
Mycobacterium avium complex (MAC) disease and cytomegalovirus retinitis (CMV) 
infection, from 21.9/100 person years in 1994 to 3.7/100 person years in 1997. In the UK, the 
increased use of HAART has been reported to be effective12 in prolonging both the incubation 
period of AIDS and survival in patients with AIDS. 
 Examination of HIV incidence rather than AIDS gives a clearer picture of trends in 
HIV infection. This can be argued as follows. Two measures of disease frequency, incidence 
and prevalence are common in epidemiology. Incidence refers to new cases of disease 
occurring among previously unaffected individuals. Point prevalence is that proportion of a 
defined population affected by the disease in question at a specified point in time. The 
numerator of the proportion comprises all those who have the disease at that instant, 
regardless of whether it was contracted recently or long ago. 
 In trend analysis of HIV infection, it is more appropriate to study incidence. This is 
because low seroincidence must be considered a requirement that an epidemic has entered a 
declining phase. The duration of survival of patients who arc HIV antibody positive, and 
hence its prevalence, may be influenced by treatment and other factors which come into play 
after diagnosis. Causal factors necessarily operate prior to diagnosis. In addition, AIDS 
incidence numbers only partially reflect HIV prevalence. 
 There has been no decrease in the overall numbers of HIV antibody positive cases in 
Ireland. This is mainly due to a recent increase among the heterosexual/risk unspecified 
group. Similar to the UK6 for HIV infection, new cases in heterosexuals now outnumber new 
cases acquired by homosexual exposure (see Table 2). This may be linked to increases in 
sexually transmitted diseases (STDs) among heterosexuals. Statistics from genitourinary 
medicine clinics13 provide the most comprehensive source of data on the epidemiology of 
STDs in the UK. Between 1995 and 1997, the total number of diagnoses of genital chlamydia, 
genital warts and Neisseria gonorrhoeae increased by 20%, 8% and 5% respectively. The 
rises have been most pronounced in 16 to 19-year-olds, both male and female. In New York 
City, high HIV seroprevalence has been associated with gonorrhoea in STD clinics.14 Thus, it 
can be argued, we may be seeing a relapse in safe sex behaviour among heterosexuals in 
Ireland. 
 We have found in this study, however, that in both the homosexual and IDU risk 
groups, reported HIV incidence is decreasing. The legalisation, public funding and expansion 
of the community-based syringe exchange programmes in New York City was associated 
with the large reductions in risk behaviour and HIV incidence among IDUs who used these 
programmes.7,15,16 
 It could be speculated that in Ireland also, similar prevention measures45 targeted at 
these risk groups, have had an impact. A study in a Dublin needle exchange reported 50% of 
respondents had not shared equipment in the previous 28 days. In addition, 25% of 
respondents used condoms always, with a further 44% using them sometimes.17 This, while 
not eliminating HIV transmission in the IDU group, may have slowed it down. 
 The total number of HIV antibody tests carried out annually has been increasing and 
has doubled in the IDU and heterosexual/risk unspecified groups in recent years. This may 
reflect a greater health awareness in the community. It may also be that more people present 
for testing so that they may benefit from treatment. Counselling policies have changed in the 
past three years to encourage testing (whereas prior to this, they may have inhibited testing). 
 The annual numbers of HIV and AIDS antibody positive cases may have been 
underestimated for the earlier years of the epidemic. This may have been through lack of 
recognition by physicians unfamiliar with the condition and, in some instances, frank 
concealment of cases. In the UK, an estimated 13% of AIDS cases go unreported.18 Thus the 
declines in incidences reported in this study may be indicative of even larger reductions. 
Conclusion 
HIV infection in Ireland is a cause for concern. A total of 2,137 positive individuals were 
reported to September 1999 – about 125 new cases reported per year in recent years. Most 
new diagnoses are recent seroconversions (Dr Clarke – clinical practice observation). This 
indicates a turning away from safe sex practices in the heterosexual/risk unspecified group 
and unsafe needle practices in the IDU group. No information is currently available on 
whether the heterosexual/risk unspecified group acquire their infection locally or abroad, 
and/or from risk group partners. Further studies on these issues would be helpful in 
identifying appropriate prevention measures. 
 Medical advances have slowed the progression of HIV disease but new infection 
remains a significant problem. None of the currently available treatments are able to 
completely eradicate the virus. Long-term treatment impairs the lives of sufferers and places a 
significant financial demand on medical resources.4 
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